The membranous nephropathy clinic nurse’s communication challenge
Primary membranous nephropathy is the most common cause of nephrotic syndrome in white adults and one of the leading causes in Hispanic adults in the United States. It is an autoimmune glomerular disease in which IgG4 antibodies directed against the M-type phospholipase A2 receptor (PLA2R) — a protein expressed on the surface of glomerular podocytes — accumulate in the subepithelial space, activate complement, and produce the terminal complement complex (C5b-9, membrane attack complex) that causes sublytic podocyte injury, foot process effacement, and the massive albumin leak that defines nephrotic-range proteinuria. In approximately seventy to eighty percent of cases, circulating anti-PLA2R IgG4 antibody titers can be measured directly, providing a biomarker that tracks immunological disease activity independently of proteinuria and eGFR. The availability of this antibody marker, combined with rituximab’s emergence as the most effective treatment for primary membranous nephropathy, creates a clinical landscape with important communication challenges: patients monitor their disease through the most visible and symptomatic signal (edema, fatigue from hypoalbuminemia) and draw conclusions about treatment necessity and disease resolution from those visible signals, while the processes that determine long-term kidney survival (ongoing podocyte injury from complement activation, progressive tubulointerstitial fibrosis from tubular proteinuria loading, B cell reconstitution restoring anti-PLA2R production) operate silently and on a timescale that does not correspond to the clinical symptoms the patient experiences.
The communication failures in the membranous nephropathy clinic cluster around three structural misunderstandings. The first is the equation of immunological remission with disease cure: a patient whose PLA2R antibody titers have fallen toward zero and whose proteinuria has reached the partial or complete remission threshold concludes that the rituximab has permanently eliminated the disease, not understanding that CD20-positive B cell depletion is temporary, that the bone marrow progenitors giving rise to new B cells are CD20-negative and unaffected by rituximab, and that the anti-PLA2R-specific B cell clone can re-emerge from reconstituting B cells within six to twelve months. The second is the equation of edema resolution with kidney disease resolution: a patient whose bilateral leg edema has disappeared on furosemide concludes that since his legs are back to normal his kidneys must be better, not understanding that furosemide and lisinopril work through entirely separate mechanisms on entirely separate pathological processes — that edema management and intraglomerular pressure reduction are not interchangeable, and that stopping lisinopril removes the efferent arteriolar dilation that reduces mechanical podocyte stress and tubular injury even when no edema is visible. The third is the failure to recognize NSAIDs as nephrotoxic in this population: a patient adds naproxen for musculoskeletal pain prescribed by a different physician without disclosing her glomerular disease, not understanding that nephrotic kidneys depend on compensatory prostaglandin E2-mediated afferent vasodilation to maintain GFR under conditions of reduced effective circulating volume, and that NSAIDs remove this critical compensatory mechanism acutely and severely, with the acute GFR reduction amplified by the independent afferent vasoconstriction produced by concurrent tacrolimus.
Three conversations from the membranous nephropathy clinic:
Scenario 1: María Elena Gutiérrez-Morales — 52 years old, Houston, Texas
María Elena Gutiérrez-Morales was a middle school teacher in Houston who had presented to nephrology after her primary care physician discovered a 3+ proteinuria on a routine urinalysis during her annual well-woman visit. Follow-up 24-hour urine collection had confirmed proteinuria at 8.4 grams per day. Her serum albumin was 2.1 g/dL. She had noticed bilateral ankle swelling over the previous six months that she had attributed to being on her feet all day at school; she had not noticed the gradual puffiness around her eyes each morning or attributed it to poor sleep. Her creatinine was 1.0 mg/dL and eGFR was 74 mL/min/1.73 m², unremarkable for her age. Serum anti-PLA2R antibody returned at 248 RU/mL (reference range <2 RU/mL, equivocal 2–20, positive >20). Serum complement C3 and C4 were normal, ANA was negative, anti-dsDNA was negative, hepatitis B surface antigen and HCV antibody were negative, serum protein electrophoresis was unremarkable, and a paraneoplastic workup (mammography, CT chest/abdomen/pelvis) was negative. The combination of nephrotic-range proteinuria and strongly positive anti-PLA2R antibody made a kidney biopsy to confirm the diagnosis clinically reasonable but immunologically certain: the biopsy was performed and confirmed PLA2R-positive primary membranous nephropathy, stage II (subepithelial deposits on electron microscopy with early spike formation on Jones silver stain, and IgG4-dominant granular subepithelial staining on immunofluorescence).
María Elena’s nephrologist explained the diagnosis in detail. The immune system was making an antibody against a protein in the kidney filters; that antibody was attaching to the filters and activating a part of the immune system that damaged the filter cells, allowing protein to leak into the urine. The goal of treatment was two-pronged: control the antibody production to allow the filter damage to heal, and simultaneously reduce the pressure and protein load on the kidneys to protect the kidney tissue while healing occurred. She was started on rituximab 1 gram intravenously, with a second infusion two weeks later (the standard rituximab protocol for membranous nephropathy established in the MENTOR trial). She was simultaneously started on lisinopril 20 mg daily to reduce intraglomerular pressure and proteinuria, and on furosemide 40 mg daily to manage the symptomatic edema and hypoalbuminemia. She was counseled that the rituximab would likely take three to six months to produce a measurable reduction in proteinuria, because the antibody deposits already in the kidney filter walls took time to clear; that she would need PLA2R antibody titer monitoring every three months; and that because rituximab’s effect was not permanent, she would need to be assessed for a repeat course at twelve months based on antibody and proteinuria trends.
The first year of treatment went well. At three months, PLA2R antibody had fallen from 248 to 68 RU/mL. At six months, PLA2R antibody was 22 RU/mL and proteinuria had begun falling, reaching 4.2 g/24h. At nine months, PLA2R antibody was 12 RU/mL (approaching the equivocal range) and proteinuria was 1.6 g/24h — meeting criteria for partial remission (proteinuria below 3.5 g/24h with a greater than fifty percent reduction from baseline). Her albumin had recovered to 3.8 g/dL; her edema had completely resolved; she had returned to feeling entirely normal at work. At the twelve-month visit, the plan had been to assess whether a second rituximab course was indicated based on the antibody trend and to consider whether she was progressing toward complete remission (proteinuria <0.3 g/24h). Her PLA2R antibody at twelve months was 8 RU/mL — still slightly above the equivocal threshold but dramatically lower than her baseline.
María Elena came to the twelve-month visit having already formed a clear conclusion: the rituximab had cured her. She felt completely well. The antibody was nearly zero. The protein was low. The edema was gone. She had done a great deal of reading online about membranous nephropathy and had found published case reports describing patients who achieved complete remission and never needed a second course. She told her clinic nurse, Patricia Cisneros-Morales, that she did not think the second rituximab course was necessary and that she planned to speak with Dr. Espinoza-García about possibly stopping the lisinopril as well once the proteinuria was below 0.3 g/24h.
Nurse Cisneros-Morales recognized that María Elena’s conclusion was understandable — indeed, a PLA2R antibody of 8 RU/mL and proteinuria of 1.6 g/24h after one rituximab course was an excellent response — but that the mechanistic inference about what the antibody normalization meant for durability was specifically incorrect in a way that determined whether a second course was needed. She asked whether she could explain what was happening in María Elena’s immune system right now, at the twelve-month mark, before the conversation with Dr. Espinoza-García, because that mechanism would change how she evaluated whether the disease was cured or controlled.
Cisneros-Morales began with what rituximab had done. Rituximab, she explained, was an antibody against a marker called CD20 that appeared on the surface of mature B cells — the immune cells that produced the anti-PLA2R antibody. When rituximab was given, it bound to CD20 on the B cells and killed them through several mechanisms: it activated the body’s complement system and cell-killing immune cells against the CD20-positive B cells, eliminating most of the circulating and tissue-resident B cell population including the anti-PLA2R IgG4-producing clones. Over the following weeks and months, the circulating anti-PLA2R antibody was cleared from the blood as the antibody-producing cells were gone; the antibody deposits already in the kidney filter walls began to be slowly cleared; and the complement activation and podocyte injury gradually ceased as the deposit load decreased. This was why the antibody titer had fallen from 248 to 8 over twelve months and why the proteinuria was following behind it downward.
But, Cisneros-Morales continued, there was a critical aspect of this that the online case reports she had read had not fully addressed. The B cells that rituximab killed were the CD20-positive mature B cells. Rituximab could not reach the bone marrow progenitor cells that gave rise to new B cells — the earliest progenitor stages of B cell development did not express CD20 yet. From the moment rituximab was infused, the bone marrow had been quietly rebuilding the B cell pool from these CD20-negative progenitors. It typically took six to nine months for B cell counts to start recovering and twelve to eighteen months for full B cell reconstitution in most patients. Right now — at month twelve — María Elena’s B cell pool was likely in early reconstitution. The question was whether, among all the new B cells being generated from the CD20-negative progenitors, any of them would become anti-PLA2R-specific IgG4-secreting cells. If the anti-PLA2R-specific memory B cell population had been stored in long-lived plasma cells or in committed CD20-negative progenitors that escaped the rituximab kill, those cells could give rise to new anti-PLA2R B cells as reconstitution proceeded. In published cohort data from membranous nephropathy rituximab trials, relapse occurred in approximately twenty-five to forty percent of patients within two to three years of the initial course, with the relapse typically signaled by a PLA2R antibody titer rise three to six months before proteinuria returned. The patients who experienced relapse had followed the same trajectory she was on — low antibody titers, falling proteinuria, partial remission — before the antibody quietly began rising again as B cell reconstitution matured and the anti-PLA2R clone re-emerged.
Cisneros-Morales then explained what the twelve-month rituximab reassessment was actually about. It was not a decision about whether a second course was needed because the first course had failed. It was a protocol-based window where the nephrologist looked at the antibody trend, the proteinuria trend, the degree of B cell reconstitution, and clinical factors to determine whether a prophylactic second course would prevent a relapse that was otherwise likely to occur during the reconstitution window — or whether the trajectory was toward sustained complete remission that might not require retreatment. That was a decision for Dr. Espinoza-García with the full clinical picture. But the starting point for that conversation was understanding that a PLA2R antibody of 8 RU/mL at month twelve represented ongoing disease suppression from the rituximab course that was now completed, not proof that the disease had permanently resolved.
She asked María Elena: “¿Si la enfermedad volviese — si el anticuerpo empezara a subir de nuevo en seis meses — querría saberlo antes de que la proteína en la orina volviera a cuatro u ocho gramos, o después?” (If the disease returned — if the antibody started rising again in six months — would you want to know before the urine protein returned to four or eight grams, or after?) María Elena answered immediately: before. Cisneros-Morales continued: “Eso es exactamente lo que el monitoreo del anticuerpo cada tres meses hace. El anticuerpo sube meses antes de que la proteína suba. Si vemos el anticuerpo subiendo, tratamos antes de que el riñón sea dañado de nuevo. Si no monitorizamos, lo primero que nota es que regresa la hinchazón y la proteína ya está alta de nuevo.” (That is exactly what the antibody monitoring every three months does. The antibody rises months before the protein rises. If we see the antibody rising, we treat before the kidney is damaged again. If we do not monitor, the first thing you notice is that the swelling returns and the protein is already high again.)
María Elena agreed to the continued monitoring and to the conversation with Dr. Espinoza-García about the twelve-month reassessment protocol. She ultimately received a second rituximab course at month thirteen based on the nephrologist’s assessment of relapse risk given her B cell count trend. Her PLA2R antibody had not risen above 12 RU/mL at eighteen months and her proteinuria continued declining toward complete remission at 0.4 g/24h at the eighteen-month follow-up.
Scenario 2: Roberto Cisneros-Espinoza — 44 years old, San Antonio, Texas
Roberto Cisneros-Espinoza was a restaurant owner in San Antonio who had been referred to nephrology after a pre-operative evaluation for an elective inguinal hernia repair revealed a serum creatinine of 1.1 mg/dL, albumin of 2.4 g/dL, and a urinalysis showing 4+ proteinuria and fatty casts. His surgeon had appropriately postponed the elective hernia repair and referred him urgently for kidney workup. On nephrology evaluation, a 24-hour urine collection confirmed proteinuria of 6.2 grams. He had bilateral lower-extremity edema to the mid-shin bilaterally, worse by the end of a day on his feet in the restaurant. He had noticed the leg swelling for approximately eight months but had attributed it to standing long hours and salt intake. His blood pressure was 138/86 mmHg on no medications. His anti-PLA2R antibody by ELISA was negative (0.8 RU/mL). A kidney biopsy was performed and showed membranous nephropathy stage II with granular IgG-dominant (but IgG1- and IgG3-dominated on subclass staining, not IgG4-dominant) subepithelial deposits — a pattern more consistent with PLA2R-negative membranous nephropathy, raising the differential of THSD7A-associated, NELL-1-associated, or exostosin 1/2-associated membranous nephropathy. Serum THSD7A antibody was negative. Given his age, the non-IgG4 subclass pattern on biopsy, and the PLA2R-negative serology, an extended paraneoplastic evaluation was performed: colonoscopy, prostate-specific antigen, CT chest/abdomen/pelvis, and PET scan were all negative.
Roberto’s nephrologist explained to him that the kidney biopsy showed the same kind of kidney disease that was produced when the immune system attacked the kidney filters, though in his case the specific antibody causing it was not yet identified. The management approach was conservative initially: optimize blood pressure and intraglomerular pressure control with lisinopril 20 mg daily, reduce edema and sodium retention with furosemide 40 mg daily, restrict dietary sodium to under 2 grams per day, and monitor closely. For PLA2R-negative membranous nephropathy, the spontaneous remission rate was approximately thirty percent over two to three years, and the decision about immunosuppressive treatment would depend on proteinuria trajectory, eGFR trajectory, and biopsy chronicity on follow-up. He was counseled about both medications: furosemide was for the swelling in his legs and the sodium retention, and would produce noticeably more urination, especially in the mornings; lisinopril was for the internal pressure in the kidney filters, would not produce symptoms he would notice, and was essential for slowing the kidney disease independent of the leg swelling.
Roberto tolerated both medications well. His edema responded dramatically to the furosemide: within four weeks, his bilateral lower extremity edema had completely resolved. His legs looked entirely normal. His weight had fallen by 5.2 kilograms, entirely from fluid loss. His blood pressure on lisinopril 20 mg was 122/74 mmHg. He felt far better than he had in months — less fatigued, less swollen, his shoes fitted again. He came to the four-week follow-up visit clearly satisfied with the treatment result, and told his nurse, María Torres-Espinoza, that he had been thinking about stopping the lisinopril because it had lowered his blood pressure “too much” and he was concerned about dizziness at work in the restaurant kitchen. He had not had any episodes of dizziness and his measured blood pressure at 122/74 was within the range Dr. Morales-García had told him was the target, but he was uncomfortable with the idea of medication that was “making the blood pressure low when the kidneys were already better.”
Nurse Torres-Espinoza heard the underlying premise: he believed the kidneys were better because the legs were better. She asked whether she could explain why those two things were different before they talked through the blood pressure concern with Dr. Morales-García.
Torres-Espinoza began with the two medications and what each one was doing, as separate operations in separate parts of the kidney. The furosemide, she explained, worked in the tubules — the long microscopic tubes that the filtered kidney fluid passed through on its way to becoming urine. Specifically, furosemide blocked a protein in the loop of the tubule that normally moved sodium from the tubular fluid back into the body; blocking this protein meant that sodium stayed in the tubular fluid and was excreted in the urine, taking water with it through osmotic effects. When extra sodium and water were removed through the urine, the body shed its excess fluid stores — the bilateral edema in his legs had been excess fluid retained because of the low albumin and because his kidneys were retaining sodium abnormally. Furosemide had corrected that sodium imbalance, and the legs had gone back to normal. What furosemide had not done, and could not do, was change anything about the immune deposits in the kidney filters, the pressure inside the tiny blood vessels of the kidney, or the amount of protein leaking from the blood into the urine. The 24-hour urine protein was still 5.8 grams — she showed him the number from the repeat collection performed two weeks earlier — essentially unchanged from his presentation level of 6.2 grams. The kidneys were still leaking protein heavily, even though his legs looked completely normal.
Lisinopril was working on an entirely different structure. The kidney’s filtration units — the glomeruli — each received blood through a small artery called the afferent arteriole and sent blood out through a small artery called the efferent arteriole. The pressure inside the glomerular capillary loop was determined by the balance of how open these two arteries were. Normally, the hormone angiotensin II preferentially tightened the efferent arteriole more than the afferent arteriole, which raised the pressure inside the glomerulus above the level of the systemic blood pressure — a feature of normal kidney design that promoted filtration. But in kidney disease with damaged filtration barriers, this elevated glomerular pressure added mechanical stress to an already-damaged filtration surface, forcing more protein through the damaged slits and also directly injuring the podocyte foot processes through mechanical stretch. Lisinopril blocked angiotensin II production, which selectively reduced the efferent arteriolar tightening and brought intraglomerular pressure down toward a less damaging level. This reduced the mechanical force driving protein through the damaged filters — that was the mechanism by which RAAS blockade reduced proteinuria, not by fixing the immune deposits but by reducing the hydraulic driving pressure. And separately, when protein at 5.8 grams per day passed through the tubules of the kidney on its way out, the tubular cells lining those tubes tried to absorb the filtered albumin and got overwhelmed; when tubular cells were overwhelmed with too much albumin to process, they activated inflammatory signaling pathways and started producing scar-forming factors that caused progressive fibrosis of the kidney’s internal architecture. Lisinopril, by reducing the proteinuria, also reduced this tubular injury and scarring signal. Neither of these mechanisms was visible as leg swelling. None of this was detectable from how his legs looked or how he felt.
She then addressed the blood pressure concern directly. A blood pressure of 122/74 in someone with kidney disease and active proteinuria was not “too low” — it was the target blood pressure specifically recommended in membranous nephropathy guidelines because the threshold for harm from the proteinuria-driven tubular fibrosis pathway was lower in proteinuric kidney disease. The dizziness concern was real and important to raise with Dr. Morales-García; there might be an adjustment to the timing or dose of lisinopril that addressed the concern. But stopping lisinopril because the legs looked better would remove the only thing protecting against the internal kidney pressure and the tubular scarring pathway, while the underlying immune process and the protein leak continued at full intensity.
Roberto asked the clarifying question that changed his frame: “¿O sea, los análisis dicen que todavía tengo casi seis gramos de proteína en la orina aunque tenga las piernas bien?” (So the tests say I still have almost six grams of protein in the urine even though my legs are fine?) Torres-Espinoza confirmed: “Sí. Las piernas bien significa que el furosemida está funcionando para el sodio y el líquido. Los análisis de protéina en orina son la única manera de saber si el riñón está mejor. Y por eso también el lisinopril es indispensable: es lo que está frenando el daño interno aunque usted no lo sienta.” (Yes. The legs being fine means the furosemide is working for the sodium and fluid. The urine protein tests are the only way to know if the kidney is better. And that is also why lisinopril is indispensable: it is what is slowing the internal damage even though you do not feel it.) He continued lisinopril. When he spoke with Dr. Morales-García, the lisinopril dose was adjusted from 20 mg at bedtime rather than morning dosing to address the orthostatic concern, which resolved the concern about dizziness at work.
Scenario 3: Ana Sofía López-Torres — 37 years old, Dallas, Texas
Ana Sofía López-Torres was a dental hygienist in Dallas who had been diagnosed with PLA2R-positive primary membranous nephropathy three years earlier, presenting with proteinuria of 7.2 g/24h, albumin 2.2 g/dL, and creatinine 0.9 mg/dL. She had received a first course of rituximab at diagnosis plus supportive lisinopril, achieved partial remission at twelve months (proteinuria 2.8 g/24h, PLA2R antibody declined from 182 to 28 RU/mL), relapsed at eighteen months (PLA2R antibody rebounded to 145 RU/mL, proteinuria 5.8 g/24h), and was treated at relapse with the second-line regimen of tacrolimus 2 mg twice daily combined with rituximab 1 gram on day 1 and day 14 per a modified STARMEN-inspired protocol. She had achieved a second partial remission on this combined regimen: at thirty months from initial diagnosis, her proteinuria was 1.8 g/24h, her PLA2R antibody was 18 RU/mL, her creatinine was 1.1 mg/dL, and her eGFR was 68 mL/min/1.73 m². She had also developed mild hypertension managed with the lisinopril 10 mg she had been on since diagnosis.
Ana Sofía had a separate, longstanding musculoskeletal problem: lumbar disc disease at L4-5 with intermittent radicular symptoms that had been managed conservatively since her late twenties with physical therapy, occasional corticosteroid epidural injections, and intermittent NSAIDs. She had been careful about NSAIDs in the context of kidney disease but had found her physiotherapist and her dentist colleagues encouraging ibuprofen and naproxen for pain management, and had generally avoided them for back pain flares out of concern since the membranous nephropathy diagnosis. During a severe back pain episode in month thirty-two of her nephropathy management, she visited a physician in Mexico while attending a family event and received a prescription for naproxen sodium 550 mg twice daily for two weeks for acute lumbar radiculopathy. She did not disclose her membranous nephropathy or her current medication list, including the tacrolimus. She filled the prescription and took naproxen for twelve days before noticing that her ankles were significantly more swollen than they had been in months and that she felt unusually fatigued and nauseous.
She called the nephrology nurse line at her Dallas clinic and spoke with nurse Carmen Reyes-Cisneros. Her home blood pressure was 148/92 mmHg, elevated above her recent baseline of 122/74 on lisinopril. Reyes-Cisneros immediately asked about any new medications or supplements. When Ana Sofía disclosed the naproxen, Reyes-Cisneros asked her to come in that afternoon for a creatinine check and to stop the naproxen immediately. The serum creatinine drawn that afternoon was 1.8 mg/dL — a rise of 0.7 mg/dL from her baseline of 1.1 mg/dL over twelve days of naproxen use. Her eGFR had fallen from 68 to approximately 41 mL/min/1.73 m². She was admitted to the nephrology observation unit for acute kidney injury evaluation and management.
Over the following three days off naproxen, her creatinine fell back toward baseline but stabilized at 1.2 mg/dL rather than fully returning to 1.1 mg/dL — suggesting that twelve days of acute GFR reduction had produced a measurable component of permanent nephron loss on top of her pre-existing membranous nephropathy-related CKD. Her edema resolved with resumed diuresis over forty-eight hours. Her blood pressure returned to 124/78 mmHg on her usual lisinopril once the NSAID effect on sodium retention had cleared.
Nurse Reyes-Cisneros had the conversation with Ana Sofía during the observation unit stay about what had happened mechanistically, both to address the acute event and to ensure that Ana Sofía understood why NSAIDs — even short courses — were specifically dangerous in her situation in a way that was different from the general NSAID caution given to healthy adults.
Reyes-Cisneros began with what the kidneys were doing under normal conditions in someone with membranous nephropathy and partial remission. Ana Sofía’s kidneys were filtering at a lower rate than a healthy kidney — her eGFR of 68 was already reduced from the normal of 90 or above. With proteinuria of 1.8 grams per day, she was losing albumin in the urine at a rate that kept her serum albumin at 3.2 g/dL — low-normal but meaningfully below the 4.5 g/dL of a healthy adult. When serum albumin was reduced, the effective volume of blood perfusing the organs was lower than the total blood volume — the kidneys sensed this and activated compensatory mechanisms to maintain blood flow to themselves. One of those compensatory mechanisms was producing prostaglandin E2 and prostacyclin locally in the walls of the arterioles delivering blood to the kidney filters. These prostaglandins dilated the afferent arterioles — the input vessels to the glomeruli — keeping them wide enough to maintain adequate filtration pressure despite the reduced circulating volume and despite the activation of angiotensin II and sympathetic signals that were trying to constrict blood vessels throughout the body.
Naproxen, she continued, blocked an enzyme called COX-2 (and COX-1) that the kidney used to produce those prostaglandins. When COX was blocked, prostaglandin E2 and prostacyclin production in the afferent arteriolar wall stopped. The compensatory vasodilation was removed. The afferent arterioles, no longer held open by prostaglandins, responded to the angiotensin II and sympathetic signals that were already present, constricting and reducing blood flow to the glomeruli. With less blood entering the glomeruli, glomerular filtration pressure fell, and the eGFR fell with it. This was an acute hemodynamic effect — not an inflammatory injury, not an immune reaction — just the kidney losing the blood flow it needed to filter at its already-reduced baseline capacity.
The tacrolimus made this worse through its own mechanism, Reyes-Cisneros explained. Tacrolimus was a calcineurin inhibitor that suppressed T cells by blocking calcineurin, but calcineurin inhibition also occurred in the smooth muscle cells of the kidney’s blood vessels. When calcineurin in vascular smooth muscle was blocked by tacrolimus, the smooth muscle cells produced less nitric oxide (a vasodilator) and more endothelin-1 (a vasoconstrictor), and the net effect was direct afferent arteriolar constriction. Ana Sofía’s afferent arterioles were already slightly constricted from the tacrolimus she had been taking for months — this was a known trade-off of the tacrolimus regimen that her nephrologist managed by keeping her tacrolimus trough levels at the low end of the therapeutic range and monitoring creatinine regularly. When naproxen was added, it eliminated the prostaglandin vasodilation that was partially compensating for the tacrolimus vasoconstriction. The combined effect was not additive in a simple way — it was synergistic: removing the compensatory vasodilation on top of the baseline tacrolimus constriction produced a disproportionate GFR fall that neither drug alone would have caused at the same doses. This was why the creatinine had risen from 1.1 to 1.8 in twelve days rather than the modest 0.1-0.2 rise sometimes seen with short NSAID courses in healthy individuals.
Ana Sofía asked what she could safely take for the back pain going forward. Reyes-Cisneros was clear: all oral NSAIDs were contraindicated for the duration of her tacrolimus treatment and likely for the life of her membranous nephropathy management. Acetaminophen (Tylenol) in doses not exceeding 3 grams per day was safe for pain because it did not inhibit renal prostaglandin synthesis at clinical doses. For severe musculoskeletal pain beyond what acetaminophen addressed, options included gabapentin or pregabalin for radicular symptoms (which she could use after nephrology and primary care coordination), short-course low-dose oral corticosteroids (which would need nephrology input because of immune suppression implications), or consultation with the nephrology team before any prescription analgesic. The critical instruction: any physician prescribing pain medication — including physicians in other countries and dentists — needed to know about the membranous nephropathy and the tacrolimus before prescribing anything anti-inflammatory.
“Lo que tengo que decir desde ahora a cualquier médico que me atienda, incluyendo mi dentista, es: tengo una enfermedad del riñón que se llama nefropatía membranosa y estoy tomando tacrolimus. Eso cambia qué medicamentos me pueden dar de manera segura.” (What I have to say from now on to any physician who treats me, including my dentist, is: I have a kidney disease called membranous nephropathy and I am taking tacrolimus. That changes which medications they can safely give me.) Reyes-Cisneros confirmed that this was exactly the instruction, and provided Ana Sofía with a wallet card listing her nephrology clinic contact number with a note that NSAID prescription required nephrology pre-authorization.
Frequently asked questions
How do membranous nephropathy clinic nurses explain why rituximab maintenance must continue even after proteinuria falls and PLA2R antibody titers normalize?
The critical mechanistic point is that rituximab depletes CD20-positive mature B cells but cannot eliminate the CD20-negative bone marrow progenitors that regenerate the B cell pool over six to twelve months. The anti-PLA2R IgG4-producing B cell clone that caused the original disease can re-emerge from reconstituting B cells — PLA2R antibody titers begin rising three to six months before proteinuria rises when relapse occurs, because antibody must accumulate in the subepithelial space to sufficient density before podocyte complement injury resumes at measurable proteinuria levels. A near-normal PLA2R antibody titer on rituximab is the drug working, not the disease permanently cured. Published relapse rates after achieving remission with one rituximab course are twenty-five to forty percent within two to three years, consistent with B cell reconstitution timelines. Monitoring PLA2R antibody titers at three-month intervals captures the re-emergence of anti-PLA2R B cell clones in the window when retreatment can prevent proteinuria relapse. The Spanish frame: “El título de anticuerpo cerca de cero es señal de que el rituximab está funcionando — no de que la enfermedad se curó. Las células B que producen el anticuerpo se regeneran en seis a doce meses de células madre que el rituximab no puede alcanzar. El anticuerpo sube meses antes de que la proteína suba — por eso lo monitorizamos: para actuar antes de que el riñón sea dañado de nuevo.” (The antibody titer near zero is the sign that rituximab is working — not that the disease was cured. The B cells that produce the antibody regenerate in six to twelve months from stem cells that rituximab cannot reach. The antibody rises months before the protein rises — that is why we monitor it: to act before the kidney is damaged again.)
How do membranous nephropathy clinic nurses explain the difference between edema resolving and proteinuria resolving, and why lisinopril must continue after bilateral edema disappears?
Furosemide and lisinopril address two entirely separate pathological processes through entirely separate mechanisms. Furosemide blocks NKCC2 in the loop of Henle, producing natriuresis and reducing total body sodium and fluid; it resolves edema driven by low oncotic pressure and primary renal sodium retention but has zero effect on glomerular proteinuria, intraglomerular pressure, or tubulointerstitial fibrosis. Lisinopril blocks angiotensin II production, selectively reducing efferent arteriolar tone and lowering intraglomerular hydraulic pressure; this reduces mechanical podocyte stress, reduces proteinuria-driven proximal tubular NF-kB and TGF-beta1 activation, and slows the tubulointerstitial fibrosis that determines long-term kidney function outcomes. Edema resolution on furosemide while proteinuria remains at 5-6 g/24h represents a kidney being actively injured by the combination of antibody-mediated podocyte damage and hyperfiltration-driven mechanical stress, with progressive tubular fibrosis advancing silently. Stopping lisinopril because the legs look normal removes the only available intervention against the intraglomerular pressure and tubular injury pathways. The Spanish frame: “Las piernas bien significa que el furosemida está funcionando. Los análisis de proteína en orina dicen si el riñón está mejor. El lisinopril baja la presión dentro de los filtros — eso no lo siente en las piernas. Si para el lisinopril porque las piernas están bien, la presión interna sube y las cicatrices internas progresan aunque las piernas sigan bien.” (The legs being fine means the furosemide is working. The urine protein tests say whether the kidney is better. Lisinopril lowers the pressure inside the filters — you do not feel that in the legs. If you stop lisinopril because the legs are fine, the internal pressure rises and the internal scarring progresses even though the legs remain fine.)